| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Critical Limb Ischemia Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Critical Limb Ischemia Therapeutics – Pipeline Assessment and Market Forecasts to 2017
The Critical Limb Ischemia Therapeutics Market is Forecast to Show Slow Growth until 2017, The report identifies the key trends shaping and driving the global critical limb ischemia market.
Hyderabad,
AP,
India
(prbd.net)
13/06/2011
GlobalData estimates that the global critical limb ischemia therapeutics market was valued at $108.4m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.4% over the next seven
years, to reach $128.2m by 2017. This slow growth is primarily attributed to no FDA approved drug for
CLI in the current market, biologics in the pipeline, low treatment seeking rate and awareness among the patients. The current competitive landscape consists of off label drugs. There are no trials being carried out on small molecules for CLI treatment.
There is no approved therapy for the treatment of CLI. All the therapies in the pipeline are biologics, which indicates that the future treatment paradigm will be mainly driven by these therapies. These novel therapies are thus classified as first-in-class, and may offer good safety and efficacy for the disease. The unmet need of the CLI therapeutics market is high, and the entry of novel biologics in the market in coming years may fulfill this huge unmet need for the treatment of the disease.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Critical-Limb-Ischemia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
GlobalData analysis shows that the CLI therapeutics pipeline is strong, with 14 therapies in various
phases of clinical development. No approved therapy for CLI classifies the therapies under trials as firstin- class. The current pipeline has only biologics, with no small molecule and only one company sponsored trial in Phase III. Phase II constitutes around 50% of the CLI pipeline, and their impact on the market will be on the later stage, leading to slow growth of the market until 2017.
GlobalData, the industry analysis specialist, has released its new report, “Critical Limb Ischemia
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global critical limb ischemia market. The report identifies the key trends shaping and driving the global critical limb ischemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable insights on the
pipeline products within the global critical limb ischemia sector. This report is built using data and
information sourced from proprietary databases, primary and secondary research, and in-house analysis
by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Critical-Limb-Ischemia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|